Welcome to our dedicated page for Reviva Pharmaceutcls Hldgs news (Ticker: RVPH), a resource for investors and traders seeking the latest updates and insights on Reviva Pharmaceutcls Hldgs stock.
Reviva Pharmaceuticals Holdings, Inc. (symbol: RVPH) is a late-stage pharmaceutical company based in San Jose, California. Located at 5941 Optical Ct, the company is renowned for discovering, developing, and seeking to commercialize innovative therapeutics for various diseases. Their primary focus areas include the central nervous system, inflammatory, and cardiometabolic diseases.
Leveraging a unique chemical genomics-driven technology platform and proprietary chemistry, Reviva aims to revolutionize treatment options. Their pipeline currently includes two prominent drug candidates:
- Brilaroxazine (RP5063): This versatile drug is intended to address multiple neuropsychiatric conditions such as schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, and Parkinson's disease psychosis.
- RP1208: Another promising candidate in their pipeline.
Reviva Pharmaceuticals continues to make strides with recent achievements and ongoing projects that keep the company at the forefront of medical innovation. For more detailed and up-to-date information, please visit their website or contact their corporate and investor relations representatives.
Reviva Pharmaceuticals Holdings announces positive results from a clinical drug-drug interaction study for brilaroxazine, a serotonin/dopamine modulator, essential for schizophrenia treatment. The study reinforces brilaroxazine's safety profile, showing no significant adverse interactions with CYP3A4 enzyme inhibitors. Topline data from the pivotal Phase 3 RECOVER trial is expected mid-2023, involving 400 patients over a 28-day regimen. The FDA may consider a 'Superior Safety' label for brilaroxazine based on positive Phase 3 results.
Reviva Pharmaceuticals (NASDAQ: RVPH) reported significant progress in its pivotal Phase 3 RECOVER trial for brilaroxazine, with over 30% patient enrollment across U.S. sites and expansion into Europe and India expected by year-end. Financially, the company recorded a net loss of $3.5 million for Q3 2022, compared to $2.3 million in Q3 2021, and had $23.2 million in cash as of September 30, 2022. Reviva anticipates topline data for the trial in mid-2023 and is exploring partnerships for further development in various neuropsychiatric and pulmonary indications.
Reviva Pharmaceuticals Holdings (NASDAQ: RVPH) announced significant progress in its Phase 3 RECOVER study for brilaroxazine, a treatment for schizophrenia, with over 30% enrollment in the U.S. and ongoing sites in Europe. The company expects to begin enrollment in Asia by November 2022. No major safety concerns have been reported in the trial, which is designed to assess brilaroxazine's efficacy across approximately 400 patients. Topline data is anticipated in mid-2023, reinforcing the potential of brilaroxazine to address the needs of approximately 24 million individuals living with schizophrenia globally.
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) announced that an interview with its Founder and CEO, Dr. Laxminarayan Bhat, will air on The RedChip Money Report on Bloomberg TV, on October 15 at 7 p.m. ET. The interview will cover the company's insider support and expected outcomes from Phase 3 trials in mid-2023. Reviva focuses on developing therapies for unmet medical needs in CNS, respiratory, and metabolic diseases. The firm is advancing two drug candidates, RP5063 and RP1208, both of which have received patent protection.
Reviva Pharmaceuticals (NASDAQ: RVPH) announced participation in the Lytham Partners Fall 2022 Investor Conference on September 28-29, 2022. CEO Laxminarayan Bhat will present a webcast at 9:00 AM ET, followed by a fireside chat and Q&A session. Investors can engage in virtual one-on-one meetings with management. Reviva focuses on developing therapies for unmet medical needs in CNS, cardiovascular, metabolic, and inflammatory diseases, with two drug candidates, RP5063 and RP1208, in its pipeline.
Reviva Pharmaceuticals Holdings (NASDAQ: RVPH) announced that its Founder and CEO, Laxminarayan Bhat, will present at the H.C. Wainwright Global Investment Conference from September 12-14, 2022. Investors can participate in virtual and in-person meetings in New York, NY. Reviva focuses on developing therapies for unmet medical needs, particularly in the central nervous system, cardiovascular, metabolic, and inflammatory diseases. The company’s pipeline includes drug candidates RP5063 and RP1208, both of which have received patent protections.
Reviva Pharmaceuticals Holdings (NASDAQ: RVPH) announced a registered direct offering of 3,359,684 shares at $2.53 per share, yielding gross proceeds of approximately $8.5 million. This offering involves a healthcare-focused institutional investor and Board member affiliates, including unregistered warrants with an exercise price of $2.40. The funds will support clinical development of brilaroxazine (RP5063) for schizophrenia and general corporate purposes. The closing is anticipated around September 8, 2022, pending customary conditions.
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) reported financial results for Q2 2022, showing a net loss of approximately $5.3 million, or ($0.29) per share, compared to $1.6 million, or ($0.12) per share, in Q2 2021. Cash reserves were approximately $19.4 million as of June 30, 2022, down from $29.7 million at the end of 2021. The company is advancing its pivotal Phase 3 RECOVER trial for brilaroxazine in schizophrenia, with over 20% of the planned 400 patients already enrolled. Topline data is expected in mid-2023, and expansion into additional indications is being explored.
Reviva Pharmaceuticals (RVPH) has announced progress in its Phase 3 clinical trial for brilaroxazine, targeting schizophrenia, with over 20% of the 400 patients already enrolled across 15 U.S. sites. Enrollment is set to expand to Europe and India in Q3 2022. Positive results from the prior Phase 2 trial support brilaroxazine’s efficacy, including a 20-point reduction in the PANSS score. Reviva plans to initiate Phase 2a trials for ADHD and Pulmonary Arterial Hypertension in Q4 2022, highlighting a robust pipeline aimed at addressing unmet medical needs.
Reviva Pharmaceuticals Holdings (NASDAQ: RVPH) announced participation in the 2022 BIO International Convention from June 13-16 in San Diego, CA. Laxminarayan Bhat, Ph.D., Founder and CEO, is set to present on June 14 at 12:15 p.m. PT. The company focuses on developing therapies for unmet medical needs in central nervous system, cardiovascular, metabolic, and inflammatory diseases. Reviva's pipeline includes RP5063 (brilaroxazine) and RP1208, both with granted patents in key markets.
FAQ
What is the current stock price of Reviva Pharmaceutcls Hldgs (RVPH)?
What is the market cap of Reviva Pharmaceutcls Hldgs (RVPH)?
What does Reviva Pharmaceuticals Holdings, Inc. specialize in?
Where is Reviva Pharmaceuticals Holdings, Inc. located?
What is Brilaroxazine (RP5063)?
What is the focus of Reviva's current pipeline?
What technology does Reviva use for drug development?
Who can be contacted for more information about Reviva Pharmaceuticals?
What other drug candidate is in Reviva's pipeline besides Brilaroxazine?
What are the therapeutic areas targeted by Reviva Pharmaceuticals?
How can I stay updated with Reviva Pharmaceuticals' latest news?
Who is the main contact for investor inquiries at Reviva Pharmaceuticals?
